17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α (CAS 1027401-98-4)
QUICK LINKS
A lot of 17-aryl trinor and 16-aryloxy tetranor prostaglandin F2α derivatives have been approved for treatment of glaucoma(1,2,3). These "ring" prostaglandin (PG) analogs have improved efficacy over the PGs with an n-alkyl lower side chain. Of these, the ones where the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects(4). 17-trifluoromethylphenyl-13,14-dihydro trinor PGF1α (17-TFM-PGF1α) is a typical "ring" analog reminiscent of trifluoromethyl-phenoxy ring of Travoprost. The a chain of 17-TFM-PGF1α is saturated, making this compound a formal member of the one-series PGs. Recent work has shown that in the "ring" series of analogs, this modification has little impact on FP receptor binding(5). As an ocular hypotensive agent, it is expected that 17-TFM-PGF1α would act like the free acid of latanoprost.
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α (CAS 1027401-98-4) References
- Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues. | deLong, MA., et al. 2000. Bioorg Med Chem Lett. 10: 1519-22. PMID: 10915040
- From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. | Stjernschantz, JW. 2001. Invest Ophthalmol Vis Sci. 42: 1134-45. PMID: 11328719
- The pharmacology of bimatoprost (Lumigan). | Woodward, DF., et al. 2001. Surv Ophthalmol. 45 Suppl 4: S337-45. PMID: 11434936
- Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. | Resul, B., et al. 1993. J Med Chem. 36: 243-8. PMID: 8423596
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α, 1 mg | sc-223181 | 1 mg | $62.00 | |||
17-trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F1α, 5 mg | sc-223181A | 5 mg | $282.00 |